[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337418-105":59,"doc-detail-337418-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","genomic-alterations-of-tumors-in-her2-low-breast-cancers","Genomic Alterations of Tumors in HER2-Low Breast Cancers","","Aim: elucidate molecular profiling in HER2-low tumors using a promising dataset. Methods: 615 consecutive HER2-negative breast cancer samples were analyzed with next-generation targeted sequencing, comparing genomic mutations across HER2-0 versus HER2-low groups and correlating mutation types with clinicopathological features. Results: the HER2-low group showed higher proportions of receptor-positive (ER/PR) and low-level Ki-67 tumors, with fewer stage I/II cases, plus a higher PIK3CA_SNA frequency (17.62% vs 9.35%, p=0.006).",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-alterations-of-tumors-in-her2-low-breast-cancers/337418/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-alterations-of-tumors-in-her2-low-breast-cancers/337418.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study on HER2-low breast cancers?","Question",{"text":112,"@type":113},"To clarify the molecular profiling of HER2-low tumors by analyzing genomic alterations and relating them to clinical and pathological characteristics.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were HER2-low and HER2-0 tumor groups compared?",{"text":117,"@type":113},"A cohort of 615 consecutive HER2-negative samples was sequenced using next-generation targeted sequencing, then genomic mutations were compared between HER2-0 and HER2-low groups.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genomic alteration showed a significant difference between HER2-low and HER2-0 groups?",{"text":121,"@type":113},"PIK3CA_SNA had a significantly higher frequency in the HER2-low group (17.62% vs 9.35%, p=0.006).",{"name":123,"@type":110,"acceptedAnswer":124},"What did the study suggest about early detection and clinical decision making?",{"text":125,"@type":113},"Early detection of PIK3CA mutations is likely important and may support therapeutic decision making in patients with HER2-low tumors.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},337418,1790173175,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Article  \nGenomic Alterations of Tumors in HER2-Low Breast Cancers  \nYi-Fang Tsai 1,2,3, Chi-Cheng Huang 1,2,4, Chih-Yi Hsu 3,5,6, Chin-Jung Feng 1,3,7, Yen-Shu Lin 1,2, Ta-Chung Chao 1,3,8, Jiun-I Lai 1,3,8, Pei-Ju Lien 1,2, Chun-Yu Liu 1,3,9,†, Jen-Hwey Chiu 1,2,10, *,† and Ling-Ming Tseng 1,2,3  \nCitation: Tsai, Y.-F.; Huang, C.-C.; Hsu, C.-Y.; Feng, C.-J.; Lin, Y.-S.; Chao, T.-C.; Lai, J.-I.; Lien, P.-J.; Liu, C.-Y.; Chiu, J.-H.; et al. Genomic Alterations of Tumors in HER2-Low Breast Cancers. Int. J. Mol. Sci. 2024, 25, 1318 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25021318  \nReceived: 22 November 2023  \nRevised: 12 January 2024  \nAccepted: 19 January 2024  \nPublished: 21 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan; [yftsai@vghtpe.gov.tw](yftsai@vghtpe.gov.tw) (Y.-F.T.); [chishenh74@gmail.com](chishenh74@gmail.com) (C.-C.H.); [cjf0205@gmail.com](cjf0205@gmail.com) (C.-J.F.); [yslin@vghtpe.gov.tw](yslin@vghtpe.gov.tw) (Y.-S.L.); [tcchao@vghtpe.gov.tw](tcchao@vghtpe.gov.tw) (T.-C.C.); [jilai@nycu.edu.tw](jilai@nycu.edu.tw) (J.-I.L.); [prlain@vghtpe.gov.tw](prlain@vghtpe.gov.tw) (P.-J.L.); [cyliu3@gmail.com](cyliu3@gmail.com) (C.-Y.L.); [lmtseng@vghtpe.gov.tw](lmtseng@vghtpe.gov.tw) (L.-M.T.)  \n2 Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan  \n3 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan; [cyhsu@vghtpe.gov.tw](cyhsu@vghtpe.gov.tw)  \n4 School of Public Health, College of Public Health, National Taiwan University, Taipei 112201, Taiwan  \n5 Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan  \n6 College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei 112201, Taiwan  \n7 Division of Plastic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan  \n8 Division of Chemotherapy, Department of Oncology, Taipei 112201, Taiwan  \n9 Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan  \n10 Division of General Surgery, Department of Surgery, Cheng-Hsin General Hospital, Taipei 112201, Taiwan  \n* Correspondence: [chiujh10@nycu.edu.tw](chiujh10@nycu.edu.tw); Tel.: +886-2-55681176 † These authors contributed equally to this work.  \nAbstract: The aim of this study was to elucidate molecular profiling in HER2-low tumors based on a promising dataset. A total of 615 consecutive HER2-negative breast cancer samples were assayed. The genomic mutations in the two groups with different HER2 expression levels (HER2-0 vs. HER2-low) were compared. The mutation types obtained via next-generation targeted sequencing were correlated with the clinicopathological features of the patients with HER2-0 and HER2-low breast cancer. The results showed that there was a significantly higher percentage of receptor-positive (ER/PR) tumors and more low-level Ki-67 tumors, but a lower incidence of stage I/II tumors in the HER2-low group compared to the HER2-0 group. There was a significantly higher frequency of 17.62%(65/369) for PIK3CA_SNA in the HER2-low group than in the HER2-0 group, which had a frequency of only 9.35%(23/246) (p = 0.006) . When the called gene alterations in the triple-negative breast cancer (TNBC) group were compared with those in the luminal-like breast cancer group, there was a significantly high frequency of 28.17%(140/497) for ERBB2_SNA in a luminal-like group than in the TNBC group(16.95%","cbCaiuaGKN6wIXSv","https://ap.wps.com/l/cbCaiuaGKN6wIXSv","pdf",13429325,13,"English","# Introduction\n## Study design and sample comparison\n## Genomic mutation analysis\n## Clinical and pathological correlations\n## Conclusions","[{\"question\":\"What is the main purpose of the study on HER2-low breast cancers?\",\"answer\":\"To clarify the molecular profiling of HER2-low tumors by analyzing genomic alterations and relating them to clinical and pathological characteristics.\"},{\"question\":\"How were HER2-low and HER2-0 tumor groups compared?\",\"answer\":\"A cohort of 615 consecutive HER2-negative samples was sequenced using next-generation targeted sequencing, then genomic mutations were compared between HER2-0 and HER2-low groups.\"},{\"question\":\"Which genomic alteration showed a significant difference between HER2-low and HER2-0 groups?\",\"answer\":\"PIK3CA_SNA had a significantly higher frequency in the HER2-low group (17.62% vs 9.35%, p=0.006).\"},{\"question\":\"What did the study suggest about early detection and clinical decision making?\",\"answer\":\"Early detection of PIK3CA mutations is likely important and may support therapeutic decision making in patients with HER2-low tumors.\"}]","Genomic Alterations of Tumors in HER2-Low Breast Cancers | PDF",1790019054,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b0e647e96733ad5927663a06eb2cd7c.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe328517b9ba0330044e8089d76e200f.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f12d898f6f800d0ca0316ce3375913.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fe796f73316ab3a8b5e20ab2e2ecd79.webp",980,1385]